Ravi Salgia

Summary

Affiliation: University of Chicago
Country: USA

Publications

  1. ncbi request reprint A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin
    Patrick C Ma
    Section of Hematology Oncology, Department of Medicine, Pritzker School of Medicine, University of Chicago Medical Center, 5841 South Maryland Avenue, Chicago, IL 60637, USA
    Clin Cancer Res 11:2312-9. 2005
  2. ncbi request reprint Novel therapies in lung cancer
    Olwen Hahn
    Department of Medicine, Section of Hematology Oncology, University of Chicago Medical Center, Cancer Research Center, Pritzker School of Medicine, 5841 South Maryland Avenue, MC 2115, Chicago, IL 60637, USA
    Hematol Oncol Clin North Am 19:343-67, vii. 2005
  3. ncbi request reprint Review of clinic trials: agents targeting c-Met
    Oyewale Abidoye
    Section of Hemato logy Oncology, Department of Medicine, The University of Chicago Medical Center, Chicago, IL 60637, USA
    Rev Recent Clin Trials 2:143-7. 2007
  4. pmc Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy
    Mari Iida
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Wisconsin Institute for Medical Research, 1111 Highland Ave, Madison, WI 53705, USA
    Mol Cancer 13:242. 2014
  5. doi request reprint A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients
    Alana Dikopf
    The University of Chicago Medicine, University of Chicago Medical Center, 5481 S Maryland Ave, Chicago, IL 60637, USA 1 773 702 4399 1 773 834 1798
    Expert Opin Drug Saf 14:485-93. 2015
  6. pmc Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer
    Michael L Maitland
    University of Chicago, Section of Hematology Oncology, 5841 S Maryland Ave, MC 2115, Chicago, IL 60637, USA
    BMC Cancer 14:5. 2014
  7. pmc Role of protein kinase C β and vascular endothelial growth factor receptor in malignant pleural mesothelioma: Therapeutic implications and the usefulness of Caenorhabditis elegans model organism
    Sivakumar Loganathan
    Section of Hematology Oncology, University of Chicago, Chicago, IL 60637, USA
    J Carcinog 10:4. 2011
  8. pmc MET/PKCbeta expression correlate with metastasis and inhibition is synergistic in lung cancer
    Leonardo Faoro
    Section of Hematology Oncology, Department of Medicine, University of Chicago Pritzker School of Medicine, and University of Chicago Cancer Research Center, Chicago, IL 60637, USA
    J Carcinog 8:15. 2009
  9. pmc Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion
    P C Ma
    Division of Hematology Oncology, Department of Medicine, University Hospitals of Case Medical Center and Ireland Cancer Center, Case Western Reserve University, Case Comprehensive Cancer Center, Cleveland, OH 44106, USA
    Br J Cancer 97:368-77. 2007
  10. pmc CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases
    Yi Hung Carol Tan
    Department of Life Science, National Taiwan Normal University, Taipei, Taiwan
    PLoS ONE 5:e8972. 2010

Detail Information

Publications141 found, 100 shown here

  1. ncbi request reprint A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin
    Patrick C Ma
    Section of Hematology Oncology, Department of Medicine, Pritzker School of Medicine, University of Chicago Medical Center, 5841 South Maryland Avenue, Chicago, IL 60637, USA
    Clin Cancer Res 11:2312-9. 2005
    ..Here, we characterized a small molecule c-MET inhibitor, PHA665752, and tested its cooperation with the mammalian target of rapamycin inhibitor as potential targeted therapy...
  2. ncbi request reprint Novel therapies in lung cancer
    Olwen Hahn
    Department of Medicine, Section of Hematology Oncology, University of Chicago Medical Center, Cancer Research Center, Pritzker School of Medicine, 5841 South Maryland Avenue, MC 2115, Chicago, IL 60637, USA
    Hematol Oncol Clin North Am 19:343-67, vii. 2005
    ..This article reviews novel therapies that are under development for non-small cell lung cancer and small cell lung cancer...
  3. ncbi request reprint Review of clinic trials: agents targeting c-Met
    Oyewale Abidoye
    Section of Hemato logy Oncology, Department of Medicine, The University of Chicago Medical Center, Chicago, IL 60637, USA
    Rev Recent Clin Trials 2:143-7. 2007
    ..With our understanding of c-Met biology and role in cancer, we should be able to arrive at a unique strategy to eradicate cancers in which c-Met plays a significant role...
  4. pmc Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy
    Mari Iida
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Wisconsin Institute for Medical Research, 1111 Highland Ave, Madison, WI 53705, USA
    Mol Cancer 13:242. 2014
    ..These findings suggest that dual targeting HER family receptors would be highly beneficial in the Ctx(R) setting...
  5. doi request reprint A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients
    Alana Dikopf
    The University of Chicago Medicine, University of Chicago Medical Center, 5481 S Maryland Ave, Chicago, IL 60637, USA 1 773 702 4399 1 773 834 1798
    Expert Opin Drug Saf 14:485-93. 2015
    ..Crizotinib is effective in NSCLC that harbors ALK translocations resulting in overexpression of oncogenic ALK fusion proteins...
  6. pmc Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer
    Michael L Maitland
    University of Chicago, Section of Hematology Oncology, 5841 S Maryland Ave, MC 2115, Chicago, IL 60637, USA
    BMC Cancer 14:5. 2014
    ..In a phase II trial that was closed to accrual because of changes in clinical practice we examined the relationships among candidate biomarkers, quantitative changes in tumor size, progression-free and overall survival...
  7. pmc Role of protein kinase C β and vascular endothelial growth factor receptor in malignant pleural mesothelioma: Therapeutic implications and the usefulness of Caenorhabditis elegans model organism
    Sivakumar Loganathan
    Section of Hematology Oncology, University of Chicago, Chicago, IL 60637, USA
    J Carcinog 10:4. 2011
    ..To examine the role of both protein kinase C (PKC)-β and vascular endothelial growth factor receptor (VEGFR)-2 in malignant pleural mesothelioma (MPM) using respective inhibitors, enzastaurin and KRN633...
  8. pmc MET/PKCbeta expression correlate with metastasis and inhibition is synergistic in lung cancer
    Leonardo Faoro
    Section of Hematology Oncology, Department of Medicine, University of Chicago Pritzker School of Medicine, and University of Chicago Cancer Research Center, Chicago, IL 60637, USA
    J Carcinog 8:15. 2009
    ..Targeted inhibition of oncogenic proteins is promising. In this study, we evaluate the expression of MET and PKCbeta and in vitro effects of their inhibition using SU11274 and enzastaurin (LY317615.HCl) respectively...
  9. pmc Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion
    P C Ma
    Division of Hematology Oncology, Department of Medicine, University Hospitals of Case Medical Center and Ireland Cancer Center, Case Western Reserve University, Case Comprehensive Cancer Center, Cleveland, OH 44106, USA
    Br J Cancer 97:368-77. 2007
    ..Investigation of mechanisms of invasion and, ultimately, metastasis in SCLC would be very useful with these signal transduction molecules...
  10. pmc CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases
    Yi Hung Carol Tan
    Department of Life Science, National Taiwan Normal University, Taipei, Taiwan
    PLoS ONE 5:e8972. 2010
    ..c-CBL is an E3 ubiquitin ligase and adaptor molecule important in normal homeostasis and cancer. We determined the genetic variations of c-CBL, relationship to receptor tyrosine kinases (EGFR and MET), and functionality in NSCLC...
  11. doi request reprint Mitochondrial dynamics: biology and therapy in lung cancer
    Frances E Lennon
    University of Chicago, Department of Medicine, Section of Hematology Oncology, 5841 S Maryland Avenue, MC 2115 Chicago, IL 60637, USA 1 773 702 4399 1 773 834 1798
    Expert Opin Investig Drugs 23:675-92. 2014
    ..Altered rates of mitochondrial fission and fusion are observed in lung cancer and can influence metabolic function, proliferation and cell survival...
  12. pmc Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer
    Rajani Kanteti
    Department of Hematology Oncology, University of Chicago Medical Center, Chicago, IL, USA
    BMC Cancer 14:185. 2014
    ..PAX8, however, is also expressed in NSCLC cell lines. We therefore investigated the role of PAX8 in NSCLC...
  13. pmc Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer
    Cleo E Rolle
    Corresponding Author Ravi Salgia, Section of Hematology Oncology, Department of Medicine, The University of Chicago, 5841 S Maryland Avenue, MC 2115, Chicago, IL 60637
    Mol Cancer Ther 13:576-84. 2014
    ..Collectively, these findings suggest that the combinatorial inhibition of MET and Top1 is a potentially efficacious treatment strategy for SCLC...
  14. pmc EphB4 as a therapeutic target in mesothelioma
    Ren Liu
    School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    BMC Cancer 13:269. 2013
    ..A search for novel targets and therapeutics is underway, and recently identified targets include VEGF, Notch, and EphB4-Ephrin-B2. Each of these targets has dual activity, promoting tumor cell growth as well as tumor angiogenesis...
  15. pmc The database of chromosome imbalance regions and genes resided in lung cancer from Asian and Caucasian identified by array-comparative genomic hybridization
    Fang Yi Lo
    Department of Pharmacology and Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, NO, 1, University Road, Tainan 701, Taiwan
    BMC Cancer 12:235. 2012
    ..Cancer-related genes show racial differences. Therefore, identification and characterization of DNA copy number alteration regions in different racial groups helps to dissect the mechanism of tumorigenesis...
  16. pmc MET as a possible target for non-small-cell lung cancer
    Ahad A Sadiq
    University of Chicago, Chicago, IL, USA
    J Clin Oncol 31:1089-96. 2013
    ..There are a number of compounds against MET/HGF in clinical trials that have been shown to be active in lung cancers. This review will summarize the biology of MET as well as its therapeutic inhibition in lung cancer...
  17. pmc Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database
    Mosmi Surati
    Pritzker School of Medicine, University of Chicago Pritzker School of Medicine, 924 E 57 St, Chicago, IL 60637
    J Clin Bioinforma 1:1-11. 2011
    ....
  18. pmc Methylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitors
    Patrick A Singleton
    Department of Medicine, University of Chicago, 5841 S Maryland Avenue, W604, Chicago, IL 60637, USA
    J Angiogenes Res 2:5. 2010
    ..Since mTOR inhibitor therapy is associated with significant side effects, we examined potential agents that can reduce the therapeutic dose...
  19. pmc Role of c-Met in cancer: emphasis on lung cancer
    Ravi Salgia
    University of Chicago, Pritzker School of Medicine, Chicago, IL, USA
    Semin Oncol 36:S52-8. 2009
    ..Several inhibitors of c-Met/HGF binding are in development, including some in phase I trials. Their effectiveness in improving cancer outcomes will be determined in the near future...
  20. pmc MET pathway as a therapeutic target
    Eric S Kim
    Section of Hematology Oncology, Department of Medicine, University of Chicago Medical Center, Chicago, Illinois 60637, USA
    J Thorac Oncol 4:444-7. 2009
    ..New drugs targeting various mesenchymal-epithelial transition factor pathways are being investigated with promising results...
  21. pmc Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer
    Ravi Salgia
    Department of Medicine, Section of Hematology Oncology, The University of Chicago, Chicago, Illinois, USA
    Cancer 117:3889-99. 2011
    ..Here the author provides an overview of angiogenic molecules currently being investigated as prognostic biomarkers in NSCLC and discusses their potential to guide treatment choices...
  22. pmc The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target
    Benjamin D Ferguson
    Pritzker School of Medicine, University of Chicago, Chicago, Illinois, USA
    PLoS ONE 8:e67668. 2013
    ..Clinical trials investigating the efficacy of anti-EphB4 therapies as well as combination therapy involving EphB4 inhibition may be warranted. ..
  23. pmc The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma
    Tanguy Y Seiwert
    Section of Hematology Oncology, Department of Medicine and University of Chicago Cancer Research Center, University of Chicago, Chicago, Illinois 60637, USA
    Cancer Res 69:3021-31. 2009
    ..MET inhibition abrogated MET functions, including proliferation, migration/motility, and angiogenesis. MET is a promising, novel target for HNSCC and combination approaches with cisplatin or EGFR inhibitors should be explored...
  24. pmc EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation
    Leonardo Faoro
    Section of Hematology and Oncology, Department of Medicine, University of Chicago, Chicago, Illinois 60637, USA
    J Biol Chem 285:18575-85. 2010
    ..Further study of EphA2 as a therapeutic target is warranted...
  25. pmc PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription
    Rajani Kanteti
    Department of Hematology Oncology, University of Chicago Medical Center, Chicago, IL 60637, USA
    Lab Invest 89:301-14. 2009
    ..Therefore, we propose that PAX5 could be an important regulator of c-Met transcription and a potential target for therapy in SCLC...
  26. pmc Protein kinase C beta in malignant pleural mesothelioma
    Leonardo Faoro
    Section of Hematology Oncology, Department of Medicine, University of Chicago Pritzker School of Medicine, Chicago, Illinois 60637 1470, USA
    Anticancer Drugs 19:841-8. 2008
    ..Enzastaurin has preclinical activity against MPM, and exhibited synergism with cisplatin. PKCbeta inhibition in MPM might be able to reduce the invasiveness of MPM by affecting cytoskeletal function...
  27. pmc Ethnic differences and functional analysis of MET mutations in lung cancer
    Soundararajan Krishnaswamy
    Department of Medicine, The University of Chicago, Chicago, Illinois, USA
    Clin Cancer Res 15:5714-23. 2009
    ....
  28. ncbi request reprint Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells
    Ramasamy Jagadeeswaran
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, Illinois 60637, USA
    Am J Physiol Lung Cell Mol Physiol 292:L1488-94. 2007
    ..c-Met is an important target in lung cancer, and the pathways responsible for ROS generation together may provide novel therapeutic intervention...
  29. pmc Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer
    Nicholas W Choong
    Section of Hematology Oncology and Phase II Network, University of Chicago Medical Center, MC 2115, 5841, S Maryland Avenue, Chicago, Illinois, USA
    J Thorac Oncol 3:1003-11. 2008
    ..This Phase I trial aimed to determine the maximum-tolerated-dose of erlotinib administered with two standard chemoradiotherapy regimens for non-small cell lung cancer...
  30. doi request reprint Differential expression of RON in small and non-small cell lung cancers
    Rajani Kanteti
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, IL 60637, USA
    Genes Chromosomes Cancer 51:841-51. 2012
    ..RON was expressed on the cell surface in NSCLC cell lines. Finally, knock down of RON expression resulted in a significant loss in viability as well as motility in lung cancer cells suggesting that RON is a potential therapeutic target...
  31. pmc MET, HGF, EGFR, and PXN gene copy number in lung cancer using DNA extracts from FFPE archival samples and prognostic significance
    Rajani Kanteti
    Department of Medicine, Section of Hematology and Oncology University of Chicago, Chicago, IL, USA
    J Environ Pathol Toxicol Oncol 28:89-98. 2009
    ..In addition, our data demonstrated that the adenocarcinoma cell lines potentially evolved under ex vivo conditions, and therefore, in genetic studies it is imperative to use primary tumors for generalized conclusions about lung tumors...
  32. pmc RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma
    Daniel V T Catenacci
    University of Chicago, USA
    Cancer Biol Ther 12:9-46. 2011
    ..These preclinical studies define RON as an important novel prognostic marker and therapeutic target for gastroesophageal cancer warranting further investigation...
  33. ncbi request reprint A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts
    Neelu Puri
    Sections of Gastroenterology and Hematology Oncology, Department of Medicine, University of Chicago Medical Center and University of Chicago Cancer Research Center, 5841 South Maryland Avenue, Chicago, IL 60607, USA
    Cancer Res 67:3529-34. 2007
    ..These studies show the feasibility of selectively targeting c-Met with ATP competitive small molecule inhibitors and suggest that PHA665752 may provide a novel therapeutic approach to lung cancer...
  34. doi request reprint Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial
    Ezra E W Cohen
    Section of Hematology and Oncology, Department of Medicine, and Comprehensive Cancer Center, University of Chicago, Chicago, IL, USA
    Clin Lung Cancer 13:123-8. 2012
    ..This trial focused on optimally combining existing targeted therapies and cytotoxic chemotherapy in the treatment of unselected patients with advanced non-small-cell lung cancer (NSCLC)...
  35. ncbi request reprint c-Met is a potentially new therapeutic target for treatment of human melanoma
    Neelu Puri
    Departments of Hematology Oncology and Pathology, University of Chicago Medical Center, Chicago, Illinois 60607, USA
    Clin Cancer Res 13:2246-53. 2007
    ..In this study, we investigated the role of c-Met in melanoma biology using a novel small-molecule tyrosine kinase inhibitor SU11274 and small interfering (si) RNA against the receptor...
  36. pmc Expression and mutational analysis of MET in human solid cancers
    Patrick C Ma
    Division of Hematology Oncology, Case Western Reserve University School of Medicine, Cleveland, OH, USA
    Genes Chromosomes Cancer 47:1025-37. 2008
    ..MET would be an important therapeutic antitumor target to be inhibited, and in lung cancer, MET may represent a cancer early progenitor cell marker...
  37. ncbi request reprint Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma
    Ramasamy Jagadeeswaran
    Section of Hematology Oncology, Department of Medicine, University of Chicago Cancer Research Center, University of Chicago Medical Center, Pritzker School of Medicine, Chicago, Illinois 60637, USA
    Cancer Res 66:352-61. 2006
    ..Ultimately, c-Met would be an important target for therapy against MPM...
  38. doi request reprint Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer
    Ichiro Kawada
    Authors Affiliations Departments of Medicine and Pathology, The University of Chicago, Chicago, Illinois
    Cancer Res 74:884-95. 2014
    ..These findings offer a robust preclinical proof of concept for MET/RON targeting by LY2801653 as a promising small-molecule modality to treat NSCLC...
  39. pmc PAX3 and SOX10 activate MET receptor expression in melanoma
    Joseph B Mascarenhas
    Section of Dermatology, Department of Medicine, University of Chicago, Chicago IL, USA
    Pigment Cell Melanoma Res 23:225-37. 2010
    ..In consequence, MET promotes the melanoma cancer phenotype by promoting migration, invasion, resistance to apoptosis, and tumor cell growth...
  40. pmc Critical role of S1PR1 and integrin β4 in HGF/c-Met-mediated increases in vascular integrity
    Yulia Ephstein
    Institute for Personalized Respiratory Medicine, Section of Pulmonary, Critical Care, and Sleep Medicine, University of Illinois at Chicago, Chicago, Illinois 60612, USA
    J Biol Chem 288:2191-200. 2013
    ..These results support a critical role for S1PR1 and ITGB4 transactivation as rate-limiting events in the transduction of HGF signals via a dynamic c-Met complex resulting in enhanced EC barrier integrity...
  41. pmc Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion
    Ramasamy Jagadeeswaran
    Department of Medicine, University of Chicago Cancer Research Center, University of Chicago Medical Center, Pritzker School of Medicine, Chicago, Illinois 60637, USA
    Cancer Res 68:132-42. 2008
    ..A murine in vivo xenograft model of A127T paxillin showed an increase in tumor growth, cell proliferation, and invasion. These results establish an important role for paxillin in lung cancer...
  42. pmc C. elegans as a model organism for in vivo screening in cancer: effects of human c-Met in lung cancer affect C. elegans vulva phenotypes
    Shahid S Siddiqui
    Section of Pulmonary and Critical Care, Department of Medicine, University of Chicago Medical Center, Pritzker School of Medicine, Chicago, Illinois 60637, USA
    Cancer Biol Ther 7:856-63. 2008
    ..elegans transgenic animals. We therefore propose the use of C. elegans as a model to rapidly assess the role of cancer specific gene mutations in the context of a whole organism...
  43. pmc PAX6 is expressed in pancreatic cancer and actively participates in cancer progression through activation of the MET tyrosine kinase receptor gene
    Joseph B Mascarenhas
    Department of Medicine, University of Chicago, Chicago, Illinois 60637, USA
    J Biol Chem 284:27524-32. 2009
    ....
  44. pmc Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia
    Halla S Nimeiri
    University of Chicago, Chicago, IL 60637, USA
    Gynecol Oncol 110:49-55. 2008
    ..The objectives of this phase II trial were to assess the activity and tolerability of the combination of bevacizumab and erlotinib in patients with recurrent ovarian, primary peritoneal or fallopian tube cancer...
  45. pmc Paxillin mutations affect focal adhesions and lead to altered mitochondrial dynamics: relevance to lung cancer
    Ichiro Kawada
    Department of Medicine, University of Chicago, Chicago, IL, USA
    Cancer Biol Ther 14:679-91. 2013
    ..The data reported herein suggest that mutant PXN variants play a prominent role in mitochondrial dynamics with direct implications on lung cancer progression and hence, deserve further exploration as therapeutic targets. ..
  46. doi request reprint Etoposide and temozolomide in combination for the treatment of progressive small-cell lung cancer central nervous system metastases: two cases
    Rimas V Lukas
    Department of Neurology, University of Chicago, Chicago, IL, USA
    Tumori 99:e73-6. 2013
    ..Progression of central nervous system (CNS) metastases from small cell lung cancer (SCLC) after radiation therapy is associated with a poor prognosis...
  47. doi request reprint Overexpression of the μ-opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis
    Frances E Lennon
    Department of Medicine, Section of Pulmonary and Critical Care, Pritzker School of Medicine, The University of Chicago, Chicago, Illinois 60637, USA
    Anesthesiology 116:857-67. 2012
    ....
  48. pmc The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation
    Biji Mathew
    University of Chicago, Chicago, Illinois, USA
    Anesth Analg 112:558-67. 2011
    ..In this study, we identify a possible mechanism for these epidemiologic findings on the basis of μ opioid receptor (MOR) regulation of Lewis lung carcinoma (LLC) tumorigenicity in cell and animal models...
  49. ncbi request reprint Chemotherapy and high dose radiotherapy followed by resection for locally advanced nonsmall cell lung cancers
    Arif Y Shaikh
    Department of Radiation and Cellular Oncology, Section of Hematology Oncology, University of Chicago, Chicago, IL, USA
    Am J Clin Oncol 30:258-63. 2007
    ..For locally advanced but technically operable nonsmall cell lung cancer (NSCLC), neoadjuvant chemoradiotherapy is frequently used. Ideal radiotherapy dose in this context is unclear...
  50. doi request reprint Lymphatic vessel density is not associated with lymph node metastasis in non-small cell lung carcinoma
    Leonardo Faoro
    Department of Medicine, Section of Hematology Oncology, University of Chicago, Chicago, IL, USA
    Arch Pathol Lab Med 132:1882-8. 2008
    ..Lymphatic metastasis is also an important means of tumor spread. In non-small cell lung carcinoma, the relationship of lymphangiogenesis with lymph node metastasis and, ultimately, patient prognosis is unknown...
  51. pmc Functional EGFR germline polymorphisms may confer risk for EGFR somatic mutations in non-small cell lung cancer, with a predominant effect on exon 19 microdeletions
    Wanqing Liu
    Department of Medicine Comprehensive Cancer Center, and Committee on Clinical Pharmacology and Pharmacogenomics, The University of Chicago, Chicago, Illinois, USA
    Cancer Res 71:2423-7. 2011
    ....
  52. doi request reprint Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers
    Rifat Hasina
    Section of Hematology Oncology, Department of Medicine, Departments of Pathology and Surgery, The University of Chicago, Chicago, IL 60637, USA
    Cancer Res 73:184-94. 2013
    ..EphB4 is robustly expressed and potentially serves as a novel biomarker for targeted therapy in esophageal cancers...
  53. pmc Paxillin expression and amplification in early lung lesions of high-risk patients, lung adenocarcinoma and metastatic disease
    Alexander C MacKinnon
    Department of Pathology, University of Chicago Medical Center, Chicago, Illinois 60637, USA
    J Clin Pathol 64:16-24. 2011
    ..A murine in vivo xenograft model of the most common paxillin mutation (A127T) showed increased cell proliferation and invasive tumour growth, establishing an important role for paxillin in the development of lung cancer...
  54. ncbi request reprint Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation
    Nicholas W Choong
    Section of Hematology Oncology, University of Chicago, Chicago, IL, USA
    Nat Clin Pract Oncol 3:50-7; quiz 1 p following 57. 2006
    ..She failed further chemotherapy treatments and subsequently developed extensive symptomatic leptomeningeal carcinomatosis associated with diplopia, hemiparesis, weight loss, and incontinence...
  55. pmc Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence
    Daniel V T Catenacci
    Department of Medicine, Section of Hematology Oncology, University of Chicago, Chicago, IL, USA
    Cancer Discov 1:573-9. 2011
    ..Tissue and serum studies evaluating the Met signaling pathway did correlate with MetMAb treatment response initially and at the time of recurrence...
  56. doi request reprint Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer
    Michael D Hasselle
    Department of Radiation and Cellular Oncology, University of Chicago, Chicago, Illinois, USA
    J Thorac Oncol 7:376-81. 2012
    ..Outcomes data treating patients with oligometastatic (≤ 5 metastases) non-small cell lung carcinoma (NSCLC) with hypofractionated image-guided radiotherapy (HIGRT) are limited...
  57. pmc Fyn: a novel molecular target in cancer
    Yoshihito D Saito
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, Illinois, USA
    Cancer 116:1629-37. 2010
    ..As several agents in clinical development affect Fyn activation, understanding the role that Fyn plays in cancer is of great importance in oncology. Cancer 2010. (c) 2010 American Cancer Society...
  58. ncbi request reprint Non-receptor tyrosine kinase inhibitors in lung cancer
    Olwen Hahn
    Department of Medicine, Section of Hematology, Oncology, University of Chicago Medical Center, Pritzker School of Medicine, Chicago, IL 60637, USA
    Anticancer Agents Med Chem 7:633-42. 2007
    ..In this article, we review non receptor tyrosine kinases' role in lung cancer and the development of agents that target these proteins...
  59. pmc Autotaxin induces lung epithelial cell migration through lysoPLD activity-dependent and -independent pathways
    Jing Zhao
    Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA
    Biochem J 439:45-55. 2011
    ..In addition we also demonstrated association of ATX with the epithelial cell-surface LPA receptor and integrin β4...
  60. pmc Expression patterns of PAX5, c-Met, and paxillin in neuroendocrine tumors of the lung
    Jie Song
    Department of Pathology, University of Chicago Medical Center, Chicago, IL, USA
    Arch Pathol Lab Med 134:1702-5. 2010
    ..The expression patterns of these functionally related proteins have not, to our knowledge, been systemically studied in neuroendocrine tumors of the lung...
  61. pmc Fyn is downstream of the HGF/MET signaling axis and affects cellular shape and tropism in PC3 cells
    Ana R Jensen
    Section of Hematology Oncology, Department of Medicine, Section of Urology, University of Chicago, Chicago, Illinois, USA
    Clin Cancer Res 17:3112-22. 2011
    ..Fyn is a member of the Src family of kinases that we have previously shown to be overexpressed in prostate cancer. This study defines the biological impact of Fyn inhibition in cancer using a PC3 prostate cancer model...
  62. pmc PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma
    Rajani Kanteti
    Department of Hematology Oncology, University of Chicago Medical Center, Chicago, IL, USA
    Sci Rep 6:32992. 2016
    ..In conclusion our findings suggest that dual inhibition of PI3K and MET pathway is an effective strategy in treating MPM as compared to a single agent. ..
  63. pmc Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer
    Benjamin D Ferguson
    Department of Surgery, University of Chicago, Chicago, Illinois, United States of America
    Sci Rep 5:10641. 2015
    ..Taken together, these data illuminate the role of EPHB4 in lung cancer and further identify EPHB4 as a potentially important therapeutic target. ..
  64. ncbi request reprint Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer
    Patrick C Ma
    Section of Hematology Oncology, Department of Medicine, University of Chicago Medical Center, Pritzker School of Medicine, Chicago, Illinois, USA
    Cancer Res 65:1479-88. 2005
    ..These results indicate that c-Met inhibition will be an important therapeutic strategy against NSCLC to improve its clinical outcome...
  65. pmc MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma
    Rajani Kanteti
    Department of Hematology Oncology, University of Chicago, Chicago, Illinois, United States of America
    PLoS ONE 9:e105919. 2014
    ..Our results suggest that the combined use of ARQ 197/NVP-BEZ235 and ARQ 197/GDC-0980 is far more effective than the use of the drugs singly in suppressing MPM tumor growth and motility and therefore merit further translational studies. ..
  66. ncbi request reprint MET and phosphorylated MET as potential biomarkers in lung cancer
    Maria Tretiakova
    University of Chicago, Department of Pathology, Chicago, Illinois 60637, USA
    J Environ Pathol Toxicol Oncol 30:341-54. 2011
    ..12- 3.07; and P = .034; HR, 1.70; 95% CI, 1.04-2.78, respectively). In summary, MET, pMET, and HGF are highly expressed in both NSCLC and SCLC. Specific forms of pMET may serve as potential biomarkers in lung cancer...
  67. pmc Lysophosphatidic acid modulates c-Met redistribution and hepatocyte growth factor/c-Met signaling in human bronchial epithelial cells through PKC delta and E-cadherin
    Yutong Zhao
    Department of Medicine, University of Chicago, Chicago, IL 60637, USA
    Cell Signal 19:2329-38. 2007
    ..These results demonstrate that LPA regulates c-Met function through PKC delta and E-cadherin in HBEpCs, suggesting an alternate function of the cross-talk between G-protein-coupled receptors (GPCRs) and RTKs in HBEpCs...
  68. doi request reprint Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer
    M Catherine Pietanza
    Department of Medicine, Thoracic Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY, USA
    J Thorac Oncol 7:856-65. 2012
    ..We undertook an open-label, multi-institutional Phase II study to investigate the efficacy and safety of XL647 in treatment-naive non-small-cell lung cancer patients clinically enriched for the presence of EGFR mutations...
  69. ncbi request reprint CD44 regulates hepatocyte growth factor-mediated vascular integrity. Role of c-Met, Tiam1/Rac1, dynamin 2, and cortactin
    Patrick A Singleton
    Department of Medicine, Pritzker School of Medicine, University of Chicago, Chicago, Illinois 60637, USA
    J Biol Chem 282:30643-57. 2007
    ..Taken together, these results suggest that CD44 is an important regulator of HGF/c-Met-mediated in vitro and in vivo barrier enhancement, a process with essential involvement of Tiam1, Rac1, dynamin 2, and cortactin...
  70. doi request reprint Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma
    Cleo E Rolle
    Department of Medicine, The University of Chicago, Chicago, IL, USA
    Oncotarget . 2016
    ..Ectopic expression of wild-type c-CBL in SCC-35 cells downregulated MET expression and decreased cell viability. These results suggest MET overexpression is related to altered c-CBL expression, which may influence tumorigenesis...
  71. pmc Lung cancer-a fractal viewpoint
    Frances E Lennon
    Section of Hematology Oncology, University of Chicago, 5841 South Maryland Avenue, MC 2115 Chicago, IL 60637, USA
    Nat Rev Clin Oncol 12:664-75. 2015
    ..Moreover, the potential use of these techniques in the diagnosis and therapeutic management of lung cancer are discussed. ..
  72. pmc The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancer
    Frances E Lennon
    Section of Pulmonary and Critical Care, Department of Medicine, Pritzker School of Medicine, The University of Chicago, Chicago, Illinois, United States of America
    PLoS ONE 9:e91577. 2014
    ..Such an effect provides a plausible explanation for the epidemiologic findings. ..
  73. ncbi request reprint Role of receptor tyrosine kinases in lung cancer
    Gautam Maulik
    Department of Adult Oncology, Dana Farber Cancer Institute, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Methods Mol Med 74:113-25. 2003
    ....
  74. doi request reprint Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma
    Andres Morales La Madrid
    Department of Pediatrics, University of Chicago, Chicago, IL, USA
    Target Oncol 7:199-210. 2012
    ..This review will discuss some of the tumor types with oncogenic ALK alterations. The activity and unique toxicities of crizotinib are described, along with potential mechanisms of resistance and new therapies beyond crizotinib...
  75. pmc Role of MetMAb (OA-5D5) in c-MET active lung malignancies
    Mosmi Surati
    University of Chicago, Pritzker School of Medicine, Chicago, IL 60637, USA
    Expert Opin Biol Ther 11:1655-62. 2011
    ..Thus far, both alone and in combination with other targeted agents, this drug has been well tolerated and no new significant safety signals have been identified...
  76. ncbi request reprint Haptoglobin alpha-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancer
    Ajit Bharti
    Department of Medicine, Center for Molecular Stress Response, Boston University School of Medicine, 88 East Newton Street, Boston, MA 02118, USA
    Anticancer Res 24:1031-8. 2004
    ..Small cell lung cancer (SCLC) frequently presents as metastatic disease. It would be useful to detect serum tumor biomarkers at an earlier stage in order to improve the overall survival...
  77. doi request reprint The role of EGFR inhibition in the treatment of non-small cell lung cancer
    Mandira Ray
    Department of Medicine, The University of Chicago, Section of Hematology Oncology and Cancer Center, Chicago, Illinois 60637, USA
    Oncologist 14:1116-30. 2009
    ..Here we discuss the clinical application of the currently available EGFR-targeted agents in NSCLC, the underlying mechanisms of resistance, and the novel agents in clinical development that may overcome resistance...
  78. ncbi request reprint Tyrosine kinase mutations in human cancer
    Ernst Lengyel
    University of Chicago, Department of Obstetrics and Gynecology, MC 2050, Section of Gynecologic Oncology, 5841 South Maryland Avenue, Chicago, IL 60637, USA
    Curr Mol Med 7:77-84. 2007
    ..It will discuss the effects that these mutations have on the biology of tumors, and how our understanding of the structure and function of kinases and their mutations is currently being used to design targeted treatments...
  79. ncbi request reprint Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer
    Syed M Ahmed
    Section of Hematology Oncology, Department of Medicine, The University of Chicago Medical Center, The Pritzker School of Medicine, Chicago, IL 60637, USA
    Respirology 11:687-92. 2006
    ..In this article, we review efforts that have been undertaken to identify genomic determinants of drug susceptibility to EGFR tyrosine kinase inhibitors, with particular focus on the role of gene mutations...
  80. ncbi request reprint Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition
    Gautam Maulik
    Department of Medicine, Division of Adult Oncology, Lowe Center for Thoracic Oncology, Binney Street, Boston, MA 02115, USA
    Cytokine Growth Factor Rev 13:41-59. 2002
    ..Finally, c-Met when mutated or over-expressed in malignant cells serves as an important therapeutic target and the most recent data in terms of inhibition of c-Met and downstream signal transduction pathways is summarized...
  81. pmc Characterization of NOL7 gene point mutations, promoter methylation, and protein expression in cervical cancer
    Colleen L Doçi
    Department of Pathology, Medicine and Radiation and Cellular Oncology, University of Chicago, Chicago, IL 60637, USA
    Int J Gynecol Pathol 31:15-24. 2012
    ..Together with evidence of its in vivo tumor suppression, these data support the hypothesis that NOL7 is the legitimate tumor suppressor gene located on 6p23...
  82. ncbi request reprint Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas
    M Kelly Nicholas
    Department of Neurology, University of Chicago, IL 60637, USA
    Clin Cancer Res 12:7261-70. 2006
    ..We will also consider the ways in which specific EGFR alterations common to glioma reflect outcomes following treatment with targeted therapies, all with an eye towards applying this understanding to improved patient outcomes...
  83. ncbi request reprint A review of topoisomerase inhibition in lung cancer
    Hatim Chhatriwala
    Department of Medicine, Griffin Hospital, Derby, Connecticut, and Boston University School of Medicine, MA, USA
    Cancer Biol Ther 5:1600-7. 2006
    ....
  84. pmc MET as a target for treatment of chest tumors
    Nicole A Cipriani
    Department of Medicine, University of Chicago Medical Center, Chicago, IL 60637, USA
    Lung Cancer 63:169-79. 2009
    ..This paper will review the structure, function, mechanisms of tumorigenesis, and potential for therapeutic inhibition of the MET receptor in lung cancer and mesothelioma...
  85. ncbi request reprint c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy
    Martin Sattler
    Department of Medicine, Pritzker School of Medicine, University of Chicago, 5841 South Maryland Avenue, Chicago, IL 60637, USA
    Curr Oncol Rep 9:102-8. 2007
    ..Targeting of the HGF/Met pathway, alone or in combination with standard therapies, is likely to improve current therapies in Met-dependent malignancies...
  86. ncbi request reprint Molecular alterations in lung cancer. Impact on prognosis
    Takashi Kijima
    Division of Adult Oncology and Thoracic Oncology Program, Department of Medicine, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Methods Mol Med 75:29-38. 2003
    ..It is hoped that with the advent of novel and directed therapeutics, we may soon show some impact on the survival of this devastating disease...
  87. doi request reprint Quality of life after radical pleurectomy decortication for malignant pleural mesothelioma
    Nathan M Mollberg
    Department of Surgery, University of Illinois, Mount Sinai Hospital, Chicago, IL 60637, USA
    Ann Thorac Surg 94:1086-92. 2012
    ..It is unknown, however, if radical surgical treatment affects quality of life (QoL) adversely. Our objective was to assess patient-reported symptoms of health-related QoL after radical pleurectomy decortication (PD)...
  88. pmc Three-dimensional stereoscopic volume rendering of malignant pleural mesothelioma
    Nathan M Mollberg
    Department of Surgery, University of Illinois at Mt Sinai Hospital, Chicago, Illinois 60637 1470, USA
    Int Surg 97:65-70. 2012
    ....
  89. pmc Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer
    Jalees Rehman
    Section of Cardiology, University of Chicago, 5841 South Maryland Ave, MC6080, Chicago, IL 60637, USA
    FASEB J 26:2175-86. 2012
    ..0 ± 19 to 87.0 ± 6 mm(3) (P<0.01) with therapeutic Drp-1 inhibition. Impaired fusion and enhanced fission contribute fundamentally to the proliferation/apoptosis imbalance in cancer and constitute promising novel therapeutic targets...
  90. pmc Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer
    Dylan M Glubb
    Department of Medicine, University of Chicago, USA
    Clin Cancer Res 17:5257-67. 2011
    ..As angiogenesis is a host-driven process, functional heritable variation in KDR, the gene encoding VEGFR-2, may affect VEGFR-2 function and, ultimately, the extent of tumor angiogenesis...
  91. ncbi request reprint The role of chemokine receptor CXCR4 in lung cancer
    Tara Gangadhar
    Department of Medicine, University of Chicago, Chicago, IL, USA
    Cancer Biol Ther 9:409-16. 2010
    ..Further understanding of the CXCR4/CXCL12 pathway in SCLC and NSCLC may provide a rationale for innovative research on the CXCR4 receptor as a potential novel therapeutic target in lung cancer...
  92. ncbi request reprint Therapeutic targeting of receptor tyrosine kinases in lung cancer
    Nicholas W Choong
    University of Chicago Medical Center, Pritzker School of Medicine, MC 2115, 5841, S Maryland Avenue, Chicago, IL 60615, USA
    Expert Opin Ther Targets 9:533-59. 2005
    ..Through understanding of receptor tyrosine kinases and the utilisation of specific inhibitors, it is hopeful that a dramatic impact will be made on the biology and therapy for lung cancer...
  93. ncbi request reprint c-Met inhibition
    Ravi Salgia
    Thoracic Oncology Research Program, Department of Medicine, Section of Hematology and Oncology, University of Chicago, USA
    Clin Adv Hematol Oncol 4:823-4. 2006
  94. ncbi request reprint Key signaling pathways and targets in lung cancer therapy
    Nicholas W Choong
    Section of Hematology Oncology, University of Chicago Medical Center, IL 60615, USA
    Clin Lung Cancer 8:S52-60. 2007
    ..Through understanding molecular targets and the utilization of specific inhibitors, hopefully, a dramatic impact will be made in the biology and therapy of lung cancer...
  95. ncbi request reprint Targeting c-Kit mutations: basic science to novel therapies
    Martin Sattler
    Department of Medical Oncology, Dana Farber Cancer Institute, Department of Medicine, Brigham and Women s Hospital, and Harvard Medical School, Boston, MA 02115, USA
    Leuk Res 28:S11-20. 2004
    ..We will also discuss the role and expression of Kit in various malignancies. Ultimately, the understanding of c-Kit biology, biochemistry, and mutational analysis will lead to better therapeutics...
  96. ncbi request reprint A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer
    Tanguy Y Seiwert
    Section of Hematology Oncology, Department of Medicine, University of Chicago, 5841 South Maryland Avenue, Chicago, IL 60637, USA
    Clin Cancer Res 13:515-22. 2007
    ..The primary objective of this phase I study was to determine the maximum tolerated dose for pemetrexed, alone and in combination with carboplatin, with concurrent radiotherapy...
  97. doi request reprint Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer
    Shengri Liao
    Department of Radiology, University of Chicago, Chicago, IL 60637, USA
    Eur J Nucl Med Mol Imaging 39:27-38. 2012
    ....

Research Grants1

  1. Studies of a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC)
    Ravi Salgia; Fiscal Year: 2011
    ..Conduct an anti-c-Met phase I/I I clinical trial against NSCLC. Through the achievement of the goals proposed in these specific aims, we will arrive at novel therapy against c- Met in lung cancer. ..